Clinical Characteristics, Management Patterns, and Outcomes of Immune Checkpoint Inhibitor-Associated Myocarditis: A Single-Center Retrospective Descriptive Study
Journal of Cardiovascular Development and Disease · 29.10.2026 · 13 (11) · 550
DOI: 10.3390/jcdd13110550 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 29.10.2026. Verfasst von Ying Zhang und 3 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Science and Technology Foundation of Hubei Province, Open Foundation of Hubei Key Laboratory, Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Immune checkpoint inhibitor-associated myocarditis (ICI-AM) is rare but potentially fatal. We retrospectively reviewed pre-existing clinical records of 42 patients diagnosed with ICI-AM at Renmin Hospital of Wuhan University between October 2023 and March 2025 and classified them as mild (grade 1–2, n = 29) or severe (grade 3–4, n = 13). Baseline characteristics, electrocardiographic findings, biomarkers, treatment patterns, and clinical outcomes were summarized descriptively. Follow-up information was retrospectively obtained from available clinical records, with an administrative follow-up end date of 31 January 2026. Severe ICI-AM was characterized by more frequent dyspnea, concomitant myasthenia gravis, electrocardiographic abnormalities, and higher troponin, CK-MB, and myoglobin levels, together with more frequent corticosteroid, intravenous immunoglobulin, and additional immunosuppressive treatment. Concomitant myositis was also more frequently observed in severe cases. During follow-up, 13 patients (31.0%) died, including 6 of 13 (46.2%) patients with severe ICI-AM and 7 of 29 (24.1%) with mild ICI-AM. Severe ICI-AM showed a more clinically overt phenotype, frequent neuromuscular involvement, and substantial all-cause mortality. These descriptive findings highlight the clinical heterogeneity of ICI-AM and require further investigation in larger prospective multicenter studies.
Förderung
- Health Science and Technology Foundation of Hubei Province
- Open Foundation of Hubei Key Laboratory
- Natural Science Foundation of Hubei Province
Zitieren
APA
Zhang, Y., Duan, H., Xu, G., & Yang, J. (2026). Clinical Characteristics, Management Patterns, and Outcomes of Immune Checkpoint Inhibitor-Associated Myocarditis: A Single-Center Retrospective Descriptive Study. Journal of Cardiovascular Development and Disease, 13(11), 550. https://doi.org/10.3390/jcdd13110550
Vancouver
Zhang Y, Duan H, Xu G, Yang J. Clinical Characteristics, Management Patterns, and Outcomes of Immune Checkpoint Inhibitor-Associated Myocarditis: A Single-Center Retrospective Descriptive Study. Journal of Cardiovascular Development and Disease. 2026;13(11):550. doi:10.3390/jcdd13110550
BibTeX
@article{Zhang2026,
author = {Zhang, Ying and Duan, Houyu and Xu, Gaoran and Yang, Junyuan},
title = {Clinical Characteristics, Management Patterns, and Outcomes of Immune Checkpoint Inhibitor-Associated Myocarditis: A Single-Center Retrospective Descriptive Study},
journal = {Journal of Cardiovascular Development and Disease},
year = {2026},
volume = {13},
number = {11},
pages = {550},
doi = {10.3390/jcdd13110550}
}
EUVIMED